fenfluramine sold brand name fintepla serotonergic medication used treatment seizures associated dravet syndrome formerly used appetite suppressant treatment obesity discontinued use due cardiovascular toxicity repurposed new fenfluramine used weight loss alone brand name pondimin combination side effects fenfluramine people treated seizures include decreased appetite somnolence sedation lethargy diarrhea constipation abnormal echocardiogram fatigue malaise asthenia ataxia balance disorder gait disturbance increased blood pressure drooling excessive salivation fever upper respiratory tract infection vomiting appetite loss weight loss falls status fenfluramine acts serotonin releasing agent agonist serotonin receptors receptor positive mechanism action treatment seizures may involve increased activation certain serotonin receptors fenfluramine developed early first introduced medical use appetite suppressant france followed approval united states fenfluramine came associated cardiovascular toxicity withdrawn united states market subsequently repurposed treatment seizures reintroduced united states european union fenfluramine previously schedule iv controlled substance united however substance since nolonger subject control pursuant rulemaking issued december fenfluramine indicated treatment seizures associated dravet syndrome syndrome people age two dravet syndrome lifethreatening rare chronic form often characterized severe unrelenting seizures despite medical fenfluramine formerly used appetite suppressant treatment obesity withdrawn use due cardiovascular common adverse reactions people seizures include decreased appetite drowsiness sedation lethargy diarrhea constipation abnormal echocardiogram fatigue lack energy ataxia lack coordination balance disorder gait disturbance trouble walking increased blood pressure drooling salivary hypersecretion saliva overproduction pyrexia fever upper respiratory tract infection vomiting decreased weight risk falls status us food drug administration fda fenfluramine labeling includes boxed warning stating drug associated valvular heart disease vhd pulmonary arterial hypertension risks vhd pah fenfluramine available restricted drug distribution program risk evaluation mitigation strategy fenfluramine rems requires health care professionals prescribe fenfluramine pharmacies dispense fenfluramine specially certified fenfluramine rems patients enrolled part rems requirements prescribers patients must adhere required cardiac monitoring echocardiograms receive higher therapeutic doses headache diarrhea dizziness dry mouth erectile dysfunction anxiety insomnia irritability lethargy cns stimulation reported reports associating chronic fenfluramine treatment emotional instability cognitive deficits depression psychosis exacerbation preexisting psychosis schizophrenia sleep suggested effects may mediated serotonergic neurotoxicitydepletion serotonin chronic administration andor activation serotonin distinctive valvular abnormality seen fenfluramine thickening leaflet chordae tendineae one mechanism used explain phenomenon involves heart valve serotonin receptors thought help regulate growth since fenfluramine active metabolite norfenfluramine stimulate serotonin receptors may led valvular abnormalities found patients using fenfluramine particular norfenfluramine potent inhibitor reuptake nerve fenfluramine active metabolite norfenfluramine affect receptors plentiful human cardiac valves suggested mechanism fenfluramine causes damage inappropriate stimulation receptors leading inappropriate valve cell division supporting idea fact valve abnormality also occurred patients using drugs act according study former users conducted plaintiffs expert cardiologist damage heart valve continued long stopping users tested women men affected exusers increase chances needing surgery faulty heart valves caused overdose fenfluramine cause serotonin syndrome rapidly result fenfluramine acts primarily serotonin releasing increases level serotonin neurotransmitter regulates mood appetite fenfluramine causes release serotonin disrupting vesicular storage neurotransmitter reversing serotonin transporter drug also acts norepinephrine releasing agent lesser extent particularly via active metabolite high concentrations norfenfluramine though fenfluramine also acts dopamine releasing agent fenfluramine may high doses addition monoamine release fenfluramine binds weakly serotonin receptors norfenfluramine binds activates serotonin receptors high affinity serotonin receptor moderate result increased serotonergic noradrenergic neurotransmission feeling fullness reduced appetite combination fenfluramine phentermine releasing agent acting primarily norepinephrine results wellbalanced releasing agent weaker effects dopamine fenfluramine identified potent positive modulator receptor action may involved therapeutic benefits treatment elimination halflife fenfluramine reported ranging mean elimination halflives enantiomers found hours dexfenfluramine hours norfenfluramine major active metabolite fenfluramine elimination halflife times long fenfluramine mean values hours dexnorfenfluramine hours fenfluramine substituted amphetamine also known racemic mixture two enantiomers dexfenfluramine analogues fenfluramine include norfenfluramine benfluorex flucetorex fludorex fenfluramine developed early introduced france approximately million europeans treated fenfluramine appetite suppression fenfluramine approved united states combination fenfluramine phentermine proposed approximately million people united states given fenfluramine dexfenfluramine without phentermine early french researchers reported association fenfluramine primary pulmonary hypertension dyspnea small sample fenfluramine withdrawn us market reports heart valve continued findings pulmonary hypertension including condition known cardiac subsequently withdrawn markets around world banned india fenfluramine appetite suppressant used treat used combination phentermine part antiobesity medication june fenfluramine approved medical use united states indication treat dravet effectiveness fenfluramine treatment seizures associated dravet syndrome demonstrated two clinical studies subjects ages two studies measured change baseline frequency convulsive studies subjects treated fenfluramine significantly greater reductions frequency convulsive seizures trials subjects received placebo inactive reductions seen within weeks remained generally consistent treatment us food drug administration fda granted application fenfluramine priority review orphan drug fda granted approval fintepla zogenix october committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product fintepla intended treatment seizures associated dravet fenfluramine approved medical use european union december fenfluramine prescription medication us fenfluramine removed schedule iv controlled substances act december unlike various amphetamine derivatives fenfluramine reported dysphoric unpleasantly lethargic nonaddictive therapeutic however reported used recreationally high doses ranging mg described producing euphoria amphetaminelike effects sedation hallucinogenic effects along anxiety nausea diarrhea sometimes panic attacks well depressive symptoms drug worn high doses eg mg mg fenfluramine induces psychedelic state resembling produced lysergic acid diethylamide indirect via induction serotonin release andor direct activation receptor would expected responsible psychedelic effects drug sufficient doses stimulants phenylethanolamine httpsenwikipediaorgwikifenfluramine